Background Image
Menu

Latest News

Extra £6.5m secured by tech firm which uses AI to speed up scientific discovery as it eyes US expansion

29 November 2022

Extra £6.5m secured by tech firm which uses AI to speed up scientific discovery as it eyes US expansion

A tech spin-out from the University of Manchester, which uses AI to curate masses of biomedical data to help scientists speed up research and development, has secured a £6.5m boost. Biorelate has completed a Series A investment round led by Maven Capital Partners and YFM...

Blueberry Therapeutics Ltd announces nomination of BB1511 for clinical development for the treatment of Atopic Dermatitis (Eczema)

23 November 2022

Blueberry Therapeutics Ltd announces nomination of BB1511 for clinical development for the treatment of Atopic Dermatitis (Eczema)

Alderley Park, 22 November 2022 – Blueberry Therapeutics are pleased to announce that their novel cream formulation for the treatment of atopic dermatitis (BB1511) has been nominated for clinical development. This nomination decision was unanimous following review of...

Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

21 November 2022

Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa

Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the first subjects have been dosed in Phase I study in healthy volunteers evaluating the Company's lead drug candidate RESP-X, a new anti-virulence therapy to treat Pseudomonas aeruginosa (Pa)...

Biorelate and Copyright Clearance Centre announce strategic integration

9 November 2022

Biorelate and Copyright Clearance Centre announce strategic integration

Manchester, UK. Biorelate Limited (“Biorelate”) and CCC (Copyright Clearance Center), have announced a strategic integration. Biorelate’s customers will immediately have the option to access subscription-only scholarly article content in XML format licensed...

First Choice Neurology partners with Cytox

8 November 2022

First Choice Neurology partners with Cytox

November 7, 2022 – First Choice Neurology (FCN), the largest neurology group in the U.S. with more than 41 facilities in six Florida counties and services at 35 major hospitals, has partnered with U.K-based Cytox to become the first practice in the United States to offer...

Oxford BioTherapeutics enters into Commercial  License Agreement with Genmab

3 October 2022

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

• OBT licenses to Genmab the rights to a novel, pre-clinical first-in-class immuno-oncology (IO) antibody. • Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing...

“Gift of time” could enable nearly 100 more kidney transplants each year

28 September 2022

“Gift of time” could enable nearly 100 more kidney transplants each year

• Kidney Research UK says that a new method of preserving donated kidneys could offer hope and the “gift of time” to save kidneys from being discarded … • The charity reveals that nearly 100 kidneys a year are not transplanted after retrieval as they are deemed...

Breakthrough in identifying risk of renal impairment in people with diabetes

8 September 2022

Breakthrough in identifying risk of renal impairment in people with diabetes

Research published in the Future of Healthcare Journal shows that models developed by UK healthtech start-up Gendius can determine which patients with type 2 diabetes are most likely to have renal impairment, allowing healthcare systems to prioritise the highest risk patients...

INFEX Therapeutics awarded Biomedical Catalyst grant for COV-X project

8 August 2022

INFEX Therapeutics awarded Biomedical Catalyst grant for COV-X project

Alderley Park, Cheshire, U.K – Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18 month, £1m COV-X project, titled: “Optimisation of a novel series of SARS-CoV-2...

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme

3 August 2022

Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme

Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive digital biomarker and drug MT1988 to...